Mucoadhesive nanoparticle delivery system
The present disclosure relates generally to a mucoadhesive nanoparticle delivery system. The nanoparticles are formed from amphiphilic macromolecules conjugated to a mucosal targeting moiety in such a manner that the surface of the nanoparticle is coated with the targeting moiety. The surface density of the targeting moiety can be tuned for adjustable targeting of the nanoparticles to a mucosal site without substantially compromising the stability of the particles. The particles were found to have high loading efficiency and sustained release properties at the mucosal site. The present disclosure also relates to polymers and macromolecules useful in the preparation of the mucoadhesive nanoparticles, as well as compositions, methods, commercial packages, kits and uses related thereto.
1. A nanoparticle composition useful for delivery of a payload to a mucosal site, the nanoparticle composition comprising a plurality of linear amphiphilic diblock copolymers that assemble to form nanoparticles of the core-shell type, wherein the nanoparticles have a hydrophobic core and a hydrophilic shell, the copolymers consisting essentially of:
a hydrophobic block comprising polylactide (PLA); and
a hydrophilic block comprising dextran, the dextran comprising multiple functional moieties,
wherein at least a portion of the functional moieties are conjugated to a phenylboronic acid (PBA) mucosal targeting moiety; and
wherein the average particle size of the nanoparticles is less than 500 nm.
2. The composition of claim 1 , wherein the nanoparticle is formed by conjugating the polylactide to the dextran to form a nanoparticle and subsequently surface-functionalizing the nanoparticle by conjugating at least a portion of the functional moieties of the dextran to the PBA to achieve a desired surface density of the PBA.
3. The composition of claim 2 , wherein substantially all of the mucosal targeting moieties are on the surface of the nanoparticle.
4. The composition of claim 1 , wherein the nanoparticle has a surface density of the mucosal targeting moiety, the surface density being tunable for adjustable targeting of the nanoparticle to the mucosal site.
5. The composition of claim 1 , further comprising a payload.
6. The composition of claim 5 , wherein the payload is a therapeutic agent.
7. The composition of claim 5 , wherein the payload is an ophthalmic agent.
8. The composition of claim 7 , wherein the ophthalmic agent is timolol, betaxolol, metipranolol, dorzolamide, cyclosporine, brinzolamide, neptazane, acetazolamide, alphagan, xalatan, bimatoprost, travaprost, olopatadine, ketotifen, acyclovir, gancyclovir, or valcyclovir.
9. The composition of claim 1 , wherein the nanoparticles are dispersed in aqueous medium.
10. A pharmaceutical composition comprising a nanoparticle composition as defined in claim 6 , and a pharmaceutically acceptable carrier.
11. The composition of claim 1 , wherein the molecular weight of the hydrophobic portion is from about 0.1 kDa to about 2000 kDa.
12. The composition of claim 1 , wherein the molecular weight of the hydrophobic portion is from about 0.5 kDa to about 200 kDa.
13. The composition of claim 1 , wherein the molecular weight of the hydrophilic portion is from about 0.1 kDa to about 1000 kDa.
14. The composition of claim 1 , wherein the molecular weight of the hydrophilic portion is from about 0.5 kDa to 100 kDa.
15. The composition of claim 1 , wherein the molecular weight of the hydrophobic portion is from about 0.1 kDa to about 2000 kDa and wherein the molecular weight of the hydrophilic portion is from about 0.1 kDa to about 1000 kDa.
16. The composition of claim 1 , wherein the average particle size of the nanoparticles is less than about 100 nm.
17. The nanoparticle of claim 1 , wherein the copolymer is Dextran-NH-Et-NH-PLA.